Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)

Inclusion Criteria: * Patients must be at least 50 years old * Neovascular age-related macular degeneration * CNV in the central part of the retina (macular is involved) * Active CNM (seen on fundus fluorescein angiography) * CNV activity is on one of the following: sub-retinal hemorrhage, sub-retinal lipid, documented loss of 3 lines of vision during last 3 months * Visual acuity of between 20/40 and 20/300 (ETDRS) Exclusion Criteria: * Patients under 50 years old * Patients with CNM not caused by AMD * Patients physically unable to tolerate intravenous fluorescein angiography * Patients with medically uncontrolled glaucoma * Patients with history of bronchial asthma, thrombophlebitis, polyvalent allergy, cancer * Any intraocular surgery within 3 months in the study eye * Prior retinal or vitreous surgery including vitrectomy or scleral buckling * Any significant ocular disease other than AMD that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome * Individuals with physical or mental disabilities that prevent accurate vision testing * History of any laser treatment of CNV in study eye (laser photocoagulation or prior photodynamic therapy), or anti-VEGF (ranibizumab or bevacizumab) in the past 2 years in the study eye.